Inpare ApS: Financial statements 2022
CVR: 37138789
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Inpare ApS (CVR 37138789) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -118,415 and a net result of DKK -142,714 compared with DKK -76,644 the year before. Equity in the 2022 report amounted to DKK -462,688.
- Gross Profit
- DKK -118,415
- Profit/Loss
- DKK -142,714
- Equity
- DKK -462,688
- Total Assets
- DKK 7,129
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -118K | -143K | -463K | - |
| 2021 | - | -98K | -77K | -320K | - |
| 2020 | - | -197K | -133K | -243K | 2 |
| 2019 | - | -100K | -78K | -110K | 2 |
| 2018 | - | -27K | -26K | -33K | 2 |
Official annual report
Keep an eye on Inpare ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Inpare ApS has published its annual report for 2021. Gross profit came to DKK -97,888, and the net result was DKK -76,644.
About Inpare ApS
Inpare ApS was a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2015. The company has been dissolved on 27 November 2024. The company was registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Lionheart Pharmaceuticals ApS. According to the 2023 annual report, the company had an average of 0 employees. In 2023, the company reported a gross profit of DKK -218,796 and a net result of DKK -272,847 compared with DKK -142,714 the year before. Equity in the 2023 report amounted to DKK -735,535.